PCSK9, a novel target for lowering LDL cholesterol: promise and progress

References

• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr. Atheroscler. Rep. 14(1), 1–10 (2012).
   Google Scholar
• Glassberg H, Rader DJ. Management of lipids in the prevention of cardiovascular events. Annu. Rev. Med. 59, 79–94 (2008).
   Google Scholar
• Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 111(12), 1795–1803 (2003).
   Google Scholar
• Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am. J. Epidemiol. 160(5), 407–420 (2004).
   Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: transcriptional mediators of lipid homeostasis. Cold Spring Harb. Symp. Quant. Biol. 67, 491–498 (2002).
   Google Scholar
• Ricotta DN, Frishman W. Mipomersen: a safe and effective antisense therapy adjunct
   Google Scholar
• Lomitapide. Am. J. Cardiovasc. Drugs 11(5), 347–352 (2011).
   Google Scholar
• Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11(5), 367–383 (2012).
   Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354(12), 1264–1272 (2006). ▪▪ Loss-of-function mutations in PCSK9 cause low LDL cholesterol (LDL-c) levels and dramatic reductions in coronary heart disease risk in the ARIC population.
   Google Scholar
• Seidah NG, Benjannet S, Wickham L et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl Acad. Sci. USA 100(3), 928–933 (2003).
   Google Scholar
• Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membranebound transcription factor. Cell 89(3), 331–340 (1997).
   Google Scholar
• Poirier S, Mayer G, Benjannet S et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol Chem. 283(4), 2363–2372 (2008).
   Google Scholar
• Graham MJ, Lemonidis KM, Whipple CP et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48(4), 763–767 (2007).
   Google Scholar
• Frank-Kamenetsky M, Grefhorst A, Anderson NN et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci.USA 105(33), 11915–11920 (2008).
   Google Scholar
• Stein EA, Mellis S, Yancopoulos GD et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366(12), 1108–1118 (2012). ▪▪ Phase I clinical trials that demonstrate safety and potent LDL-lowering effects of REGN727 monoclonal antibody to PCSK9 in normocholesterolemic and heterozygous familial hypercholesterolemia patients.
   Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59(25), 2344–2353 (2012). ▪▪ Inhibition of PCSK9 lowers LDL-c by 40–70% in patients with primary hypercholesterolemia.
   Google Scholar
• Du F, Hui Y, Zhang M, Linton MF, Fazio S, Fan D. Novel domain interaction regulates secretion of proprotein convertase subtilisin/ kexin type 9 (PCSK9) protein. J. Biol Chem. 286(50), 43054–43061 (2011).
   Google Scholar
• Fan D, Yancey PG, Qiu S et al. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry 47(6), 1631–1639 (2008).
   Google Scholar
• Chan JC, Piper DE, Cao Q et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl Acad. Sci. USA 106(24), 9820–9825 (2009). ▪▪ Demonstration that a monoclonal antibody to PCSK9 lowers LDL-c in nonhuman primates.
   Google Scholar
• Ni YG, Di Marco S, Condra JH et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J. Lipid Res. 52(1), 78–86 (2011).
   Google Scholar
• Liang H, Chaparro-Riggers J, Strop P et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J. Pharmacol. Exp. Ther. 340(2), 228–236 (2012).
   Google Scholar
• Stein EA, Gipe D, Bergeron J et al. Effect of a monoclonal antibody to PCSK9, REGN727/ SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a Phase 2 randomised controlled trial. Lancet 380(9836), 29–36 (2012). ▪▪ Phase II clinical trial demonstrates efficacy and safety of monoclonal antibodies to PCSK9 for cholesterol lowering in 77 patients with heterozygous familial hypercholesterolemia.
   Google Scholar
• Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein b and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler. Thromb. Vasc. Biol. 32(7), 1585–1595 (2012).
   Google Scholar
• Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors. Science 212(4495), 628–635 (1981).
   Google Scholar
• Roth EM, McKenney JM, Hanotin C et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. doi:10.1056/ NEJM oa1201832 (2012) (Epub ahead of print).
   Google Scholar
• Sullivan D, Olsson AG, Scott R et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients. The GAUSS randomized trial. JAMA 1–10 (2012).
   Google Scholar
• Raal F, Scott R, Somaratne R et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proproteinconvertasesubtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 126(20), 2408–2417 (2012).
   Google Scholar
• Giugliano RP, Desai NR, Kohli P et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, Phase 2 study. Lancet pii: S0140–S6736(12)61770-X (2012).
   Google Scholar
• Koren MJ, Scott R, Kim JB et al. Efficacy, safety, and tolerability of a monoclonal antibody to proproteinconvertasesubtilisin/ kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, Phase 2 study. Lancet pii: S0140–S6736(12)61771-1 (2012).
   Google Scholar
• Gumbiner B, Udata C, Joh T et al. The effects of multiple dose administration of RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin Type 9, in hypercholesterolemic subjects. Circulation 126, A13524 (2012).
   Google Scholar